is a promising prognostic, immunological, and therapeutic biomarker in human tumors.

Despite past research linking mutations to cancer development, no pan-cancer analyses of have been published. As a result, we utilized multiple databases to illustrate the potential roles of in diverse types of cancers. Several databases were used to assess expression in the TCGA cancer samples. Additional assessments were undertaken to investigate the relationship between and overall survival, immune cell infiltration, genetic alterations, promoter methylation, and protein-protein interaction. HLF's putative roles and the relationship between expression and drug reactivity were investigated. expression was shown to be lower in tumor tissues from a variety of malignancies when compared to normal tissues. There was a substantial link found between expression and patient survival, genetic mutations, and immunological infiltration. HLF influenced the pathways of apoptosis, cell cycle, EMT, and PI3K/AKT signaling. Abnormal expression of lowered sensitivity to numerous anti-tumor drugs and small compounds. According to our findings, reduced expression drives cancer growth, and it has the potential to be identified as a vital biomarker for use in prognosis, immunotherapy, and targeted treatment of a range of malignancies.